98 related articles for article (PubMed ID: 29500135)
1. Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model.
Falke J; Hulsbergen-van de Kaa CA; Maj R; Oosterwijk E; Witjes JA
Urol Oncol; 2018 May; 36(5):242.e1-242.e7. PubMed ID: 29500135
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
Falke J; Hulsbergen-van de Kaa CA; Maj R; Oosterwijk E; Witjes JA
World J Urol; 2018 Nov; 36(11):1719-1725. PubMed ID: 29767328
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.
Falke J; Lammers RJ; Arentsen HC; Ravic M; Pozzi R; Cornel EB; Vergunst H; de Reijke TM; Witjes JA
J Urol; 2013 Jun; 189(6):2077-82. PubMed ID: 23206424
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.
Donin NM; Chamie K; Lenis AT; Pantuck AJ; Reddy M; Kivlin D; Holldack J; Pozzi R; Hakim G; Karsh LI; Lamm DL; Belkoff LH; Belldegrun AS; Holden S; Shore N
Urol Oncol; 2017 Feb; 35(2):39.e1-39.e7. PubMed ID: 28341495
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer.
Arends TJ; Lammers RJ; Falke J; van der Heijden AG; Rustighini I; Pozzi R; Ravic M; Eisenhardt A; Vergunst H; Witjes JA
Clin Genitourin Cancer; 2015 Jun; 13(3):204-9.e2. PubMed ID: 25660383
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects.
Crain B; Yao S; Keophilaone V; Promessi V; Kang M; Barberis A; Maj R; Mura E; Passini N; Holldack J; Ochoa R; Cottam HB; Carson DA; Hayashi T
Eur J Dermatol; 2013; 23(5):618-28. PubMed ID: 24225049
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs.
Arentsen HC; Hulsbergen-Van de Kaa CA; Jansen CF; Maj R; Leoni LM; Oosterwijk E; Witjes JA
BJU Int; 2011 Oct; 108(7):1210-4. PubMed ID: 21314886
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Hayashi T; Crain B; Corr M; Chan M; Cottam HB; Maj R; Barberis A; Leoni L; Carson DA
Int J Urol; 2010 May; 17(5):483-90. PubMed ID: 20337728
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intravenous and intravesical administration of chloro-aluminum sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model.
Bachor R; Flotte TJ; Scholz M; Dretler S; Hasan T
J Urol; 1992 May; 147(5):1404-10. PubMed ID: 1569696
[TBL] [Abstract][Full Text] [Related]
10. Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers.
Xiao Z; Brown K; Tulip J; Moore RB
J Urol; 2003 Jan; 169(1):352-6. PubMed ID: 12478188
[TBL] [Abstract][Full Text] [Related]
11. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer.
Blietz CE; Thode B; Hauses M; Pries R; Meyer AJ; Doehn C; Jocham D; Kausch I
In Vivo; 2009; 23(1):13-9. PubMed ID: 19368119
[TBL] [Abstract][Full Text] [Related]
12. Intravesical Chemotherapy and Chemohyperthermia in Non-Muscle-Invasive Bladder Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics.
Campodonico F; Di Stasi S; Lev GM; Terrone C; Bongiovanni L; Mattioli F; Pagliarulo V; Introini C
Curr Drug Metab; 2017; 18(7):657-665. PubMed ID: 28460622
[TBL] [Abstract][Full Text] [Related]
13. No inhibition of urinary bladder carcinogenesis in rats with intravesical instillation of alpha-galactosylceramide.
Mitsuhashi M; Wanibuchi H; Wei M; Doi K; Morimura K; Masuda C; Wada S; Nakatani T; Kakizoe T; Fukushima S
Asian Pac J Cancer Prev; 2003; 4(1):45-50. PubMed ID: 12718700
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
Smith EB; Schwartz M; Kawamoto H; You X; Hwang D; Liu H; Scherr DS
J Urol; 2007 Jun; 177(6):2347-51. PubMed ID: 17509356
[TBL] [Abstract][Full Text] [Related]
15. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
Xiao Z; Mak A; Koch K; Moore RB
BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
[TBL] [Abstract][Full Text] [Related]
16. Monocyte targeting and activation by cationic liposomes formulated with a TLR7 agonist.
Johansen PT; Zucker D; Parhamifar L; Pourhassan H; Madsen DV; Henriksen JR; Gad M; Barberis A; Maj R; Andresen TL; Jensen SS
Expert Opin Drug Deliv; 2015 Jul; 12(7):1045-58. PubMed ID: 25682882
[TBL] [Abstract][Full Text] [Related]
17. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
[No Abstract] [Full Text] [Related]
18. Editorial comment from Dr Olbert to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Olbert PJ
Int J Urol; 2010 May; 17(5):491. PubMed ID: 20415709
[No Abstract] [Full Text] [Related]
19. Editorial comment from Dr Arum to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Arum CJ
Int J Urol; 2010 May; 17(5):490. PubMed ID: 20415708
[No Abstract] [Full Text] [Related]
20. The fluorescence biodistribution and kinetics of aminolevulinic acid induced protoporphyrin IX in the bladder of a rat model with orthotopic urothelial carcinoma.
Gronlund-Pakkanen S; Wahlfors J; Makinen K; Pakkanen TM; Talja M; Ala-Opas M; Alhava E; Moore RB
J Urol; 2002 Apr; 167(4):1848-53. PubMed ID: 11912446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
